Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction regarding the US Retirement Savings Plan.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK Ordinary share ADRs), an increase in the notional allocation of Ordinary Share ADRs occurred on February 6, 2009. The transaction price was $37.12 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: February 6, 2009.
- Transaction Price: $37.12 per ADR.
- Involved Parties: Dr M M Slaoui (16 ADRs), Mr W C Louv (8 ADRs), and Dr D Pulman (11 ADRs).
- Instrument: Notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan.